{"id":56363,"date":"2024-06-19T00:05:16","date_gmt":"2024-06-19T00:05:16","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/06\/19\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/"},"modified":"2024-06-19T00:05:16","modified_gmt":"2024-06-19T00:05:16","slug":"tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/","title":{"rendered":"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma"},"content":{"rendered":"<div>\n<p><em>Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET<\/em><\/p>\n<p align=\"justify\">BRISBANE, Calif., June  18, 2024  (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class<sup>i<\/sup> targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase 1b\/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET.<\/p>\n<p align=\"justify\">To join the conference call via phone and participate in the live Q&amp;A session, please pre-register online <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UUqwVMEh4pKBdyjtPvP0QFg2B_bFqKRssHu8AcmTRK0I_827VaGQMx7zxxE4REufTZzR5CAVg6W4_NZhQqK3PiEkmjBNjTR3OqOIW8zfx8SCy5XyNusCuUSvrq73bBKYwWaGQgOreQEj2Hu-z92nSg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>here<\/u><\/a> to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the investor section of the Tempest website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JMCTYfYOaP_WUP9cz24FTQAc0pA3XJ1iLJ1kjZQPsBgfFh0otdN3vWLDvNlemZrk4_UQJRAcR5B7ce42L_7oq_iB-lbpPrg9DNTS6wUnNSc=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/ir.tempesttx.com\/<\/u><\/a>. The webcast will be available for replay for 30 days.<\/p>\n<p align=\"start\"><strong>About Tempest Therapeutics<\/strong><\/p>\n<p align=\"justify\">Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and\/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company\u2019s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXP1nwAFS1FSzBf4WikBCnOVZKlczXK57YszE5ydE1vGfitF5XM9ZpnRYDUL_RGvQFSd2cR-4Wshh39oa6L-HTGMOnz-y2DN734EtiH9Mlo=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>www.tempesttx.com<\/u><\/a>.<\/p>\n<p align=\"start\"><strong>Investor &amp; Media Contacts<\/strong><\/p>\n<p align=\"start\">Sylvia Wheeler <br \/> Wheelhouse Life Science Advisors <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7AbNd6hrjNGZOy5QVx0MdvrXb5VXtaRBz1PdqVCWU-8LRAku2BtGtoO2w-aTP6uX9HO_n1x04tRFaALKjT6Ryeb2UOXF7viizFet8O1HUHbw7CGHeSlCDHXSHF2uomAJ\" rel=\"nofollow noopener\" target=\"_blank\" title=\"swheeler@wheelhouselsa.com\">swheeler@wheelhouselsa.com<\/a><\/p>\n<p align=\"start\">Aljanae Reynolds <br \/> Wheelhouse Life Science Advisors <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yc9MAfM2zRkFo5Y1brbSjt-GjUNSxixxNk1uPWuNXCCcopAYol9CCC4xfqEH0n-5SX9sSwO9LTlvjbTETzQBjhFjeML_8NpY3NYWNMWVlr9zqS8yvrh4tt_bH2_ec8RD\" rel=\"nofollow noopener\" target=\"_blank\" title=\"areynolds@wheelhouselsa.com\">areynolds@wheelhouselsa.com<\/a><\/p>\n<table style=\"border-collapse: collapse; width:307px; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; text-align: left ;  vertical-align: middle; \"><sup>i<\/sup> If approved by the FDA<\/td>\n<\/tr>\n<\/table>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmY5MmM4OTctMmNhYy00NDUzLWFmZjctYjY5M2M5N2I5YTkyLTEyMDE0ODc=\/tiny\/Tempest-Therapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase 1b\/2 combination study [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-56363","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, In\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-19T00:05:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/06\/Tempest-Therapeutics.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma\",\"datePublished\":\"2024-06-19T00:05:16+00:00\",\"dateModified\":\"2024-06-19T00:05:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\"},\"wordCount\":277,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\",\"name\":\"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-06-19T00:05:16+00:00\",\"dateModified\":\"2024-06-19T00:05:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma","og_description":"Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, In","og_url":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-06-19T00:05:16+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/06\/Tempest-Therapeutics.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma","datePublished":"2024-06-19T00:05:16+00:00","dateModified":"2024-06-19T00:05:16+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/"},"wordCount":277,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/","url":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/","name":"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-06-19T00:05:16+00:00","dateModified":"2024-06-19T00:05:16+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Tempest to Report New Data from Global\u00a0Randomized Combination Study of Amezalpat (TPST-1120)\u00a0in First-Line Hepatocellular Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=56363"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56363\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=56363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=56363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=56363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}